Rezzayo

(Rezafungin)

Rezzayo

Drug updated on 11/17/2023

Dosage FormInjection (intravenous: 200 mg as a solid (cake or powder) in a single-dose vial for reconstitution)
Drug ClassEchinocandin antifungal
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.

Product Monograph / Prescribing Information

Document TitleYearSource
Rezzayo (rezafungin) Prescribing Information. 2023Patheon Italia S.p.A., a Thermo Fisher Scientific company, Monza, Italy

Systematic Reviews / Meta-Analyses